Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Clevidipine emulsion formulations containing antimicrobial agents|
|Abstract:||Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.|
|Inventor(s):||Motheram; Rajeshwar (Dayton, NJ), Williams; Gregory Charles (Bernardsville, NJ)|
|Assignee:||The Medicines Company (Parsippany, NJ)|
1. A pharmaceutical formulation comprising (a) an effective amount of clevidipine, or a pharmaceutically acceptable salt or ester, (b) an antimicrobial agent, EDTA,
present at about 0.001 to about 1.5% w/v, (c) a lipid, (d) an emulsifier, (e) a tonicity modifier, and (f) water wherein the formulation is resistant to microbial growth.
2. The pharmaceutical formulation of claim 1, wherein EDTA is present at about 0.001 to about 0.025% w/v.
3. The pharmaceutical formulation of claim 1, wherein the lipid is selected from the group consisting of soybean oil, safflower seed oil, olive oil, cottonseed oil, sunflower oil, sesame oil, peanut oil, corn oil, medium chain triglycerides, triacetin, propylene glycol diesters, monoglycerides, and a mixture of two or more thereof.
4. The pharmaceutical formulation of claim 1, wherein the emulsifier is selected from the group consisting of egg yolk phospholipids, soybean phospholipids, synthetic phosphatidyl cholines, purified phosphatidyl cholines and hydrogenated phosphatidyl choline, and mixtures of two or more thereof.
5. The pharmaceutical formulation of claim 1, further comprising an antioxidant selected from the group consisting of sodium ascorbate, sodium citrate, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, tocopherol, and a pharmaceutically acceptable salt thereof.
6. The pharmaceutical formulation of claim 1 having a pH of about 6.0 to about 8.8.
7. The pharmaceutical formulation of claim 2, further comprising a co-emulsifier wherein the co-emulsifier is selected from the group consisting of glycerin, poloxamers, polyoxyethylene castor oil derivative, poloxamines, polyoxyethylene stearates, polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, polysorbates, tocopherol PEG succinate, cholic acid, deoxycholic acid, oleic acid, and pharmaceutically acceptable salts thereof.
8. The formulation of claim 1 wherein microbial growth is delayed or retarded such that there is less than 10-fold (1 log) increase in viable microbial colonies over a 24-hour period.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.